Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from GlucoTrack ( (GCTK) ).
On February 3, 2025, Glucotrack, Inc. implemented a one-for-twenty reverse stock split, reducing the number of its outstanding common shares significantly. This corporate action, approved by shareholders, aims to streamline the company’s stock structure and possibly improve its market positioning. Additionally, on February 4, 2025, Glucotrack announced the successful completion of its first in-human clinical study of a continuous blood glucose monitor, marking a significant milestone in diabetes technology. The study met its primary safety endpoints and demonstrated the potential for more accurate glucose monitoring, which could enhance the company’s standing in the medical technology field.
More about GlucoTrack
Glucotrack, Inc. is a medical technology company focused on designing, developing, and commercializing novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system.
YTD Price Performance: -82.84%
Average Trading Volume: 46,686,471
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.95M
For a thorough assessment of GCTK stock, go to TipRanks’ Stock Analysis page.
